EUVIMEDEUVIMED entdecken
Crossref

Resistant Hypertension

Muhammad Shahzeb Khan, Muhammad Sameer Arshad iD, Michael E Hall, Tazeen H Jafar iD, Anandita Kulkarni, Nicholas W S Chew iD, Daniel W Jones, Karol Watson iD, Matthew R Weir iD, Javed Butler

Clinical Journal of the American Society of Nephrology · 02.10.2026

DOI: 10.2215/cjn.0000001266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 02.10.2026. Verfasst von Muhammad Shahzeb Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Baylor Scott and White Research Institute, Dallas, Texas. Die Arbeit nennt 82 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistant hypertension (RHTN), defined as BP above target despite treatment with at least 3 antihypertensive agents (including a diuretic) or controlled BP requiring 4 or more medications, affects over 140 million individuals globally and confers increased risks of heart failure, stroke, and CKD progression. A considerable proportion of cases represent apparent RHTN, in which pseudo-resistance because of inaccurate BP measurement, medication nonadherence, or white-coat effect has not yet been excluded. Ambulatory and home BP monitoring is therefore central to confirming true resistance and identifying high-risk phenotypes, including nocturnal hypertension and abnormal dipping patterns. Excluding pseudo-resistance and secondary causes remains essential before escalating therapy. RHTN commonly coexists with obesity, type 2 diabetes, and CKD and is driven by overlapping mechanisms of aldosterone excess, sodium and water retention, and sympathetic activation. Guideline-directed treatment centers on optimization of lifestyle measures and triple therapy with renin–angiotensin system blockade, a calcium channel blocker, and a thiazide-like diuretic, followed by a mineralocorticoid receptor antagonist as preferred fourth-line agent. In patients with CKD, careful assessment of volume status, diuretic selection, kidney function, and hyperkalemia risk is particularly important. Recent therapeutic advances have expanded options for patients who remain uncontrolled. Newly US Food and Drug Administration–approved agents aprocitentan and baxdrostat provide additional pharmacologic options for patients inadequately controlled on existing therapy. Renal denervation offers a separate device-based approach for selected patients, whereas investigational RNA-based and other neuromodulatory therapies may further broaden future treatment options. Future management is likely to move toward more precise, phenotype-guided treatment integrating ambulatory BP patterns, renin–aldosterone biology, volume status, kidney function, and cardiometabolic comorbidities. Improved diagnostic precision and mechanism-based treatment strategies may reduce persistent treatment gaps and improve long-term cardiovascular and kidney outcomes.

Schlagwörter

Stichwörter der Autor:innen

hypertension

Autor:innen und Institutionen

  • Baylor Scott and White Research Institute, Dallas, Texas.
  • Baylor Scott and White The Heart Hospital Plano, Plano, Texas.
  • Department of Medicine, Baylor College of Medicine, Temple, Texas.
  • Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi.
  • Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore.
  • Department of Cardiology, National University Heart Centre, National University of Health System, Singapore.

ORCID-Profile: Muhammad Sameer Arshad, Tazeen H Jafar, Nicholas W S Chew, Karol Watson, Matthew R Weir

Zitieren

APA

Khan, M. S., Arshad, M. S., Hall, M. E., Jafar, T. H., Kulkarni, A., Chew, N. W. S., Jones, D. W., Watson, K., Weir, M. R., & Butler, J. (2026). Resistant Hypertension. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001266

Vancouver

Khan MS, Arshad MS, Hall ME, Jafar TH, Kulkarni A, Chew NWS, et al. Resistant Hypertension. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001266

BibTeX
@article{Khan2026,
  author = {Khan, Muhammad Shahzeb and Arshad, Muhammad Sameer and Hall, Michael E and Jafar, Tazeen H and Kulkarni, Anandita and Chew, Nicholas W S and Jones, Daniel W and Watson, Karol and Weir, Matthew R and Butler, Javed},
  title = {Resistant Hypertension},
  journal = {Clinical Journal of the American Society of Nephrology},
  year = {2026},
  doi = {10.2215/cjn.0000001266}
}
Kostenlos starten →